Last updated: 2026-09-05 19:52:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Aurinia Pharmaceuticals Inc. (AUPH) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16.08, with a market capitalization of $2.17B and a P/E ratio of 6.83. Over the past 52 weeks, its price has ranged from $10.34 to $19.25. This page covers its latest market performance, valuation, price trends and company information.
$2.17B | |
$15.97 | |
$33.97 | |
$1.41 | |
$16.12 | |
421.53K | |
-- | |
6.83 | |
$19.25 | |
$10.34 | |
-- | |
-- |
Aurinia Pharmaceuticals Inc. (AUPH) last closed at $16.12 as of 2026-09-04 23:56:00, unchanged from the previous close of $16.12.
During the latest regular trading session, AUPH traded between $1.41 and $33.97, with a volume of 421.53K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Aurinia Pharmaceuticals Inc. (AUPH) moved from $16.21 to $16.08, representing a decline of 0.81% ($0.13).
The stock traded between $15.93 and $16.22 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 744.85 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 64.4%
AUPH is currently trading at $16.08, placing it 64.4% of the way from its 52-week low of $10.34 to its 52-week high of $19.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 128 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aurinia Pharmaceuticals Inc. (AUPH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.